- Home
- DT vs INCY Comparison
DT vs INCY Comparison
Compare DT & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- INCY
- Stock Information
- Founded
- DT 2005
- INCY 1991
- Country
- DT United States
- INCY United States
- Employees
- DT N/A
- INCY N/A
- Industry
- DT Computer Software: Prepackaged Software
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- DT Technology
- INCY Health Care
- Exchange
- DT Nasdaq
- INCY Nasdaq
- Market Cap
- DT 14.8B
- INCY 13.4B
- IPO Year
- DT 2019
- INCY 1993
- Fundamental
- Price
- DT $43.10
- INCY $58.21
- Analyst Decision
- DT Buy
- INCY Hold
- Analyst Count
- DT 26
- INCY 20
- Target Price
- DT $60.29
- INCY $74.00
- AVG Volume (30 Days)
- DT 3.2M
- INCY 2.3M
- Earning Date
- DT 05-14-2025
- INCY 04-29-2025
- Dividend Yield
- DT N/A
- INCY N/A
- EPS Growth
- DT 143.79
- INCY N/A
- EPS
- DT 1.60
- INCY 0.15
- Revenue
- DT $1,634,366,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- DT $21.56
- INCY $12.21
- Revenue Next Year
- DT $15.07
- INCY $9.20
- P/E Ratio
- DT $26.93
- INCY $345.39
- Revenue Growth
- DT 19.81
- INCY 14.76
- 52 Week Low
- DT $39.30
- INCY $50.35
- 52 Week High
- DT $63.00
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- DT 35.61
- INCY 40.69
- Support Level
- DT $42.53
- INCY $57.05
- Resistance Level
- DT $44.18
- INCY $59.95
- Average True Range (ATR)
- DT 2.06
- INCY 2.76
- MACD
- DT 0.11
- INCY 0.18
- Stochastic Oscillator
- DT 39.42
- INCY 46.45
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.